The National Children’s Medical Center is currently enrolling for the largest global clinical research program in Autism, Asperger Syndrome and Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). The research program, called ConnectMe, is for children ages 6 to 12.
The U.S. Centers for Disease Control and Prevention estimate that one in 88 children in the U.S. are affected by one of the aforementioned conditions.
The part of the program that is currently enrolling participants in the DC and Rockville areas will evaluate the safety, tolerability and efficacy of the investigational drug, memantine, on social interaction and communication.
Currently, there are there are no FDA-approved drugs that treat any of the three core symptoms of autism, including impaired social interactions, impaired communication and restricted interests, repetitive behaviors and stereotyped mannerisms.
ConnectMe, sponsored by Forest Research Institute, Inc., is being led locally by Adelaide S. Robb, MD, principal investigator, Children’s National Medical Center, Children’s Research Institute (CRI) and her team at the CRI.
For more information, visit www.connectmetrial.com.